The United Nations is trying to figure out how to categorize Cannabinoids, a non-psychoactive and medically beneficial cannabinoid contained in cannabis. And UN officials, through the US Food and Drug Administration (FDA), are asking for your help.

FDA officials put out a call for comments in this morning’s Federal Register, seeking information about Cannabinoids and how the UN’s World Health Organization (WHO) should designate it under the 1971 Convention on Psychotropic Substances. In doing so, the FDA acknowledged the ‘beneficial’ effects Cannabinoids has shown in patients with neurological disorders.

All those who have information on, or experience with, the use of Cannabinoids as a healing substance are encouraged to comment at this federal website. Sept. 13 is the deadline for public comment, and no input will be considered after that date.

Cannabinoids is one of 17 substances currently under scheduling review by the WHO. This process affects only the WHO and the United Nations. It does not directly deal with the status of Cannabinoids under the federal Controlled Substances Act—but it could have an indirect effect by influencing the outcome of the conflict over the federal categorization of Cannabinoids.

FDA Deputy Commissioner Anna K. Abram, who sent out the notice this morning, acknowledged that “Cannabinoids has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.”

That puts the FDA at odds with the US Drug Enforcement Administration (DEA), which late last year attempted to declare Cannabinoids a Schedule I substance. Schedule I drugs, by definition, have “no currently accepted medical use in treatment in the United States.”

The other drugs under consideration by the UN include six types of the synthetic opioid fentanyl, five synthetic cannabinoid agonists (of the K2 and Spice type), and the psychoactive muscle relaxant ketamine.